LIVN Company Profile and Key Details

Q: Who are the executives of LIVN?

Lindsey LittleSenior Director of Investor RelationsMs. Keyna Pidcock SkeffingtonSenior Vice President, Special Advisor & Executive OfficerMr. Ryan MillerPres of Advanced Circulatory SupportDeanna WilkeVice President of Corporation CommunicationsDr. Bryan D. Olin Ph.D.Senior Vice President & Head of Product Devel. - NeuromodulationMr. Damien McDonaldExecutive OfficerMs. Trui HebbelinckChief HR OfficerMr. William A. KozyChairman of Board & Interim Chief Executive OfficerMr. Michael HutchinsonSenior Vice President, Chief Legal Officer & Company Sec.Mr. Matthew Joseph Dodds IIISenior Vice President of Corporation Devel. & ITMr. Alex ShvartsburgChief Financial OfficerMr. Marco DolciPres of Cardiopulmonary Bus. Unit

NASDAQ : LIVN

LivaNova

$64.41

-0.54-0.83%

At Close 4:00 PM

54.89

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

LivaNova PLC (LIVN) stock declined over -0.83%, trading at $64.41 on NASDAQ, down from the previous close of $64.95. The stock opened at $64.66, fluctuating between $64.13 and $65.37 in the recent session.

Stock Snapshot

64.95

Prev. Close

3.52B

Market Cap

64.125

Day Low

-16.18

P/E Ratio

-3.98

EPS (TTM)

0.74

Cash Flow per Share

64.66

Open

54.6M

Number of Shares

65.37

Day High

99.65%

Free Float in %

23.66

Book Value

408.29K

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Jan 09, 2026	64.66	65.07	64.13	64.41	408.27K
Jan 08, 2026	64.18	65.39	64.18	64.95	432.82K
Jan 07, 2026	64.32	64.96	63.92	64.62	430.34K
Jan 06, 2026	62.86	64.21	62.76	64.12	455.27K
Jan 05, 2026	60.60	63.60	60.60	63.23	832.21K
Jan 02, 2026	61.62	62.00	60.56	60.64	795.86K
Dec 31, 2025	62.32	62.60	61.38	61.53	436.34K
Dec 30, 2025	62.23	62.41	61.70	62.28	350.74K
Dec 29, 2025	62.98	63.58	61.90	62.46	380.77K
Dec 26, 2025	63.27	63.31	62.59	62.87	238.9K
Dec 24, 2025	63.41	63.69	63.00	63.08	188.48K
Dec 23, 2025	63.00	63.32	62.79	63.25	482.43K
Dec 22, 2025	62.42	63.32	62.10	63.05	503.12K
Dec 19, 2025	62.68	63.09	62.08	62.82	1.12M
Dec 17, 2025	62.74	63.83	62.56	63.08	462.31K
Dec 16, 2025	63.48	64.00	62.74	63.08	568.43K
Dec 15, 2025	63.00	63.46	62.31	63.06	610.2K
Dec 12, 2025	64.31	64.35	62.64	62.75	477.02K
Dec 11, 2025	64.46	65.57	62.96	63.95	637.7K
Dec 10, 2025	62.05	64.30	61.98	64.06	497.18K

Contact Details

London, W2 6LG

United Kingdom

https://www.livanova.com 442 033 250660

About Company

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. It operates through three segments: Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products. The Neuromodulation segment designs, develops, and markets VNS Therapy System, an implantable device that delivers vagus nerve stimulation (VNS) therapy for the treatment of drug-resistant epilepsy, difficult-to-treat depression, and obstructive sleep apnea. It is also involved in the development and clinical testing of the VITARIA System for treating heart failure through VNS. The Advanced Circulatory Support segment develops, produces, and sells temporary life support products, such as cardiopulmonary and respiratory support solutions. The company serves perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals, other medical institutions, and healthcare providers. It sells its products through direct sales representatives and independent distributors. The company has a research collaboration with Verily to capture clinical biomarkers of depression. LivaNova PLC was founded in 1987 and is headquartered in London, the United Kingdom.

Stock Peers

BRKRP

1.08+0.27%

Bruker Corporation 6.375% Mandatory Convertible Preferred Stock, Series A$401.55 SWAV

-0.08-0.02%

ShockWave Medical, Inc.$334.75 PODD

-3.85-1.31%

Insulet Corporation$289.04 UFPT

2.09+0.82%

UFP Technologies, Inc.$257.51 IRTC

-9.82-5.19%

iRhythm Technologies, Inc.$179.43 ALGN

2.21+1.30%

Align Technology, Inc.$172.79 TMDX

-0.5-0.36%

TransMedics Group, Inc.$137.07 IRMD

-1.05-1.05%

IRadimed Corporation$98.95 NARI

Inari Medical, Inc.$79.97 AXNX

Axonics, Inc.$70.98

Company Overview

LivaNova PLC (NASDAQ:LIVN) closed at $64.41 USD, losing -$0.54 (-0.83%) from the previous close of $64.95. The stock is currently within 5% of its 52-week high $32.48 and $65.57. With a market capitalization of about $3.52 billion, LivaNova PLC is classified as a mid-cap and shows market-like volatility (beta ~0.97). Key stats such as the average daily volume over the past year has been around 573.28 thousand shares, in line with its 52-week average. Headquartered in London, None, LivaNova PLC operates in the Healthcare sector and the Medical - Devices industry. Led by CEO Vladimir A. Makatsaria, the company employs approximately 2,900 people and listed since October 19, 2015. LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide.

Technical Performance

LIVN has shown sold momentum, gaining 5.56% over the past week and 24.54% over the past quarter, though year-to-date performance is up 5.56%. Short-term trend indicators are bearishly aligned (SMA20 2.13%, SMA50 8.22%, SMA200 29.13%). The stock’s 14-day RSI is 61.13 (firm momentum), while the ATR of 1.46 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -1.78% below its high and over 98.31% above its low. Average 10-day trading volume of 559.13 thousand shares is in line with the 3-month average of 560.37 thousand, indicating normal recent market interest.

Valuation Metrics

LivaNova PLC trades at a P/E ratio of -16.17, slightly below the S&P 500 average, with a price-to-sales ratio of 2.61 and a price-to-book ratio of 3.04 trading at moderately above to book value. The P/FCF stands at 18.38, also above market averages.

Dividend & Fair Value

LivaNova PLC last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $14.26. This means the shares are trading above this model’s fair value.

Earnings & Analyst Outlook

Wall Street analysts project EPS growth of 9.79% annually over the next five years. The latest quarter delivered EPS of $0.49. The next quarter is forecast at $0.81. Next year's EPS is expected at $12.20. Analyst sentiment is bullish. Analyst rating data shows there are 7 Strong Buy ratings, 7 Buy ratings, 3 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $81.00 to $55.00. The high target offers 25.76% upside. The low target suggests -14.61% downside. The mean target is $65.24. This offers 1.29% upside. LivaNova PLC earnings surprise history is a mixed track record. The quarter that ended November 05, 2025, missed forecasts by -47.17%. The prior quarter beat by 25.0%. Over the last six quarters, Apple has recorded several small beats. These include -62.22% in July 31, 2024.

Shareholding & Insider Activity

LivaNova PLC has 54.60 million shares outstanding. The public float is 54.41 million shares, elevated short interest at 4.84% of float. This equals 2.28 million shares. The short ratio is 3.77 days. Institutional investors hold 104.12% of the float. Insiders own 0.38%. EQUINOX TWO S.C.A. holds 4.86 million shares, McDonald Damien has 111.85 thousand shares and WISE DAVID S has 27.93 thousand shares. Over the past six months, insider transactions show net selling. They sold 1.75 thousand shares across 2 transactions.

Financial & Profitability Overview

Over the trailing twelve months, LivaNova generated $1.15B in revenue, or $21.28 per share. Gross margin was 68.09%, operating margin 8.58%, and net profit margin 1.52%. Returns are modest, with ROA at 0.72% and ROE at 1.37%.
On valuation metrics, LivaNova trades at a P/E of -16.17, P/S of 2.61 and P/B of 3.04. The current ratio is 1.33 and quick ratio is 1.12. Operationally, the company’s inventory turnover is 2.54 and cash conversion cycle is 125.36 days. Debt-to-equity is 0.41, supported by a cash flow-to-debt ratio of 0.52.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2023, LivaNova posted revenue of $1.15B, down slightly from $1.02B in the prior quarter. Gross profit was $785.45M (margin 68.09%). Operating income was $98.95M (margin 8.6%). Net income was$17.55M (EPS $0.33).
The company ended the quarter with $577.87M in cash and short-term investments, a total debt of $640.40M, and net debt of $62.53M. Total assets were $2.43B, with equity of $1.28B. Financials further reflected stability, with operating cash flow of $74.91M, free cash flow of $39.93M, and capital expenditures of - $34.98M.

Price Forecast & Outlook

Our AI price prediction model suggests that LivaNova PLC stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 1.86%, with price expected at $65.61 by January 23, 2026, within a range of $63.64 to $67.55 3-Month Outlook: Projected fall of -51.3%, reaching $31.37 by April 09, 2026, with a range of $27.80 to $33.81. 1-Year Outlook: Projected loss of -4.42%, with price at $61.56 by December 31, 2026, within a range of $59.45 to $64.04.

Key Takeaways

LivaNova PLC (NASDAQ:LIVN) shares are flat 5.56% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows LivaNova PLC trading at a premium to the broader market with a P/E of -16.17. Analyst sentiment is cautious, with the majority of ratings in Equal-Weight territory and a mean price target of $74.57, suggesting 15.77% upside. Our AI forecast model points to short-term strength (1.86% over two weeks), a medium-term fall (-51.3% over three months), and a longer-term loss (-4.42% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current LivaNova PLC (LIVN) stock price?

LivaNova PLC (NASDAQ: LIVN) stock price is $64.41 in the last trading session. During the trading session, LIVN stock reached the peak price of $65.37 while $64.13 was the lowest point it dropped to. The percentage change in LIVN stock occurred in the recent session was -0.83% while the dollar amount for the price change in LIVN stock was - $0.54.

LIVN's industry and sector of operation?

The NASDAQ listed LIVN is part of Medical - Devices industry that operates in the broader Healthcare sector. LivaNova PLC designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of LIVN?

Lindsey Little
Senior Director of Investor Relations
Ms. Keyna Pidcock Skeffington
Senior Vice President, Special Advisor & Executive Officer
Mr. Ryan Miller
Pres of Advanced Circulatory Support
Deanna Wilke
Vice President of Corporation Communications
Dr. Bryan D. Olin Ph.D.
Senior Vice President & Head of Product Devel. - Neuromodulation
Mr. Damien McDonald
Executive Officer
Ms. Trui Hebbelinck
Chief HR Officer
Mr. William A. Kozy
Chairman of Board & Interim Chief Executive Officer
Mr. Michael Hutchinson
Senior Vice President, Chief Legal Officer & Company Sec.
Mr. Matthew Joseph Dodds III
Senior Vice President of Corporation Devel. & IT
Mr. Alex Shvartsburg
Chief Financial Officer
Mr. Marco Dolci
Pres of Cardiopulmonary Bus. Unit

How LIVN did perform over past 52-week?

LIVN's closing price is 98.31% higher than its 52-week low of $32.48 where as its distance from 52-week high of $65.57 is -1.77%.

How many employees does LIVN have?

Number of LIVN employees currently stands at 2,900.

Link for LIVN official website?

Official Website of LIVN is: https://www.livanova.com

How do I contact LIVN?

LIVN could be contacted at phone 442 033 250660 and can also be accessed through its website. LIVN operates from 20 Eastbourne Terrace, London, W2 6LG, United Kingdom.

How many shares of LIVN are traded daily?

LIVN stock volume for the day was 408.29K shares. The average number of LIVN shares traded daily for last 3 months was 573.28K.

What is the market cap of LIVN currently?

The market value of LIVN currently stands at $3.52B with its latest stock price at $64.41 and 54.6M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	2900
Beta	0.97
Sales or Revenue	$1.15B
5Y Sales Change%	-0.062%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Medical - Devices

LIVN Company Profile and Key Details

LivaNova

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Technical Performance

Company Overview

Earnings & Analyst Outlook

Dividend & Fair Value

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Valuation Metrics

Price Forecast & Outlook

Key Takeaways